Question 1

How much BPC-157 to take for inflammation?

Accepted Answer

No study among the research behind this page has given BPC-157 to a person for an inflammatory condition and reported an amount. A 2025 systematic review describes the anti-inflammatory signal as preclinical: in animal models the compound reduced inflammatory cytokines, the chemical messengers that drive swelling. And a 2026 review in the American Journal of Sports Medicine states that information regarding the indications, dosing, frequency, and duration of treatment remains unknown. So the outcome has only been measured in animals. Even there, the amounts probed a range rather than landing on a number. The 2003 rat Achilles study tested 10 micrograms, 10 nanograms and 10 picograms per kilogram of body weight. That is a spread of a million to one, which is how you map a dose-response curve and not how you set a protocol. No study we could find has shown that those figures scale up to a person by body weight, and we do not publish that sum.

Question 2

What is the recommended dosing protocol for BPC-157?

Accepted Answer

There is none. No regulator, no clinical guideline and no trial among the research behind this page has established a dosing protocol for BPC-157 in people. A 2026 review says as much directly: indications, dosing, frequency and duration all remain unknown. A 2025 literature review notes that the compound has not been approved for use in standard medicine by the FDA or other global regulators, because sufficient clinical studies in humans are absent. In the 2003 rat Achilles study the compound was given once daily into the abdominal cavity, dosed per kilogram of body weight. A 2021 review describes the wider pattern across the rodent literature: the same dose range and the same equipotent routes were used regardless of which injury was being tested. That is one research programme holding its inputs fixed and varying the injury rather than the amount. A protocol is something a clinician follows for a patient. This is the opposite, a fixed experimental input used to compare outcomes across models.

Question 3

How long should I cycle off of BPC-157?

Accepted Answer

No study among the research behind this page has tested a cycle, a break or a taper, so there is no interval to report. In the rat Achilles experiment, administration ran once daily from 30 minutes after the injury until 24 hours before the animal was examined. Assessments fell on days 1, 4, 7, 10 and 14. That is a continuous course tied to an injury and ending when the experiment ended, rather than a cycle with an off-period built into it. The 2025 systematic review reports that BPC-157 is metabolised in the liver, has a half-life of less than 30 minutes, and is cleared by the kidneys. A half-life that short means the compound itself is unlikely to build up between daily injections. That is a statement about clearance, not about whether a tissue effect persists, builds or fades. A 2026 review lists duration among the things that remain unknown.

Question 4

How much BAC water to mix with BPC-157 10mg?

Accepted Answer

Reconstitution is arithmetic, and the arithmetic does not depend on any protocol. A 10 mg vial holds 10,000 micrograms of powder, so adding 2 mL of bacteriostatic water leaves the vial at 5,000 micrograms per mL, and adding 5 mL leaves it at 2,000 micrograms per mL. The diluent volume sets the concentration, not how much compound is in the glass. FDA enforcement records list a 10 mg BPC 157 injection from a Florida pharmacy, recalled in December 2018 for lack of sterility assurance. They list 2000 mcg/mL in 5 mL vials from a Houston infusion firm, recalled a year later for the same reason. They list a 2 mg/mL, 5 mL presentation from a Texas compounder, recalled in 2022. What no study among the research behind this page supplies is the other half of the sum, the amount a person would be drawing up. In the research behind this page, that figure has not been established, so the arithmetic stops at concentration rather than continuing to a volume.

Question 5

How much BPC-157 is effective?

Accepted Answer

In rats, a very wide range produced an effect. Rats whose right Achilles tendon had been cut received 10 micrograms, 10 nanograms or 10 picograms per kilogram of body weight, once daily, into the abdominal cavity. The paper reports that BPC 157 fully improved recovery in those rats against saline controls, judged biomechanically, functionally, microscopically and macroscopically. A range that wide producing a result is interesting. It is also a warning: the experiment was not built to find a minimum effective amount, and none was reported. For a person, no equivalent figure exists. A 2019 review notes that the majority of studies have been performed on small rodent models and that efficacy in humans is yet to be confirmed. Scaling an animal amount by body surface area is not a validated procedure for this compound, which is why this page reports parameters rather than converting them.

Question 6

Do you need to cycle off of BPC-157?

Accepted Answer

No study among the research behind this page has tested that, so the honest answer has to be built from what was measured. Continuous daily administration is what the animal experiments did, over courses of about two weeks in the Achilles work. Nothing in that design says what happens at week six or week twelve, because the experiments ended. The pharmacokinetic picture — pharmacokinetics being how a compound moves through and out of the body — is short: liver metabolism, a half-life under 30 minutes, kidney clearance. That argues against the compound itself accumulating. It says nothing about tolerance, receptor changes or rebound, and none of those has been measured for BPC-157 in any species. A 2025 narrative review describes the human evidence as three pilot studies, one of them looking at intravenous safety. Cycle lengths quoted elsewhere are not derived from any of this.

Question 7

How to dilute 5 mg of BPC-157?

Accepted Answer

The same arithmetic, on a different vial: 5 mg is 5,000 micrograms, so 1 mL of bacteriostatic water gives 5,000 mcg/mL, 2 mL gives 2,500 mcg/mL, and 5 mL gives 1,000 mcg/mL. On a U-100 insulin syringe each unit mark is 0.01 mL, which means that at 2,500 mcg/mL a single unit mark holds 25 micrograms of compound. That is a conversion rather than a suggestion, because which mark anyone would draw to depends on an amount that no source covered here has established for a person. FDA records show 5 mL vials of this kind in circulation: a 2000 mcg/mL, 5 mL vial distributed through an Indianapolis institute was recalled in November 2020 because production processes could not assure the sterility of products intended to be sterile. That is the pattern across every documented FDA action on compounded BPC-157: the question was sterility, rather than how much was in the vial.

Question 8

How do you determine how much BPC-157 to take?

Accepted Answer

We will not answer that with a number. There is no published human amount to report, so any figure given would have to come from converting an animal one. A 2026 review states that indications, dosing, frequency and duration all remain unknown. Animal-to-human conversion is the specific trap. The rat Achilles experiment expressed everything per kilogram of body weight, which makes it look convertible, but per-kilogram scaling across species is not validated for this compound and no published work performs it. What can be determined from the literature is narrower and still useful: the routes that have been studied, how often animals were given it, how long those courses ran, and the concentration in a vial once it has been reconstituted. Reported animal parameters and an amount for a person are different questions, and only the first of them has an answer.

Question 9

How long does a 10mg vial of BPC-157 last?

Accepted Answer

Two questions hide inside that one, and only one of them has an answer. How long the contents last as chemistry, once reconstituted, is not addressed in the published literature on this compound. How many draws a vial contains is arithmetic you can only finish with a figure no study among the research behind this page has published: a 10 mg vial holds 10,000 micrograms whatever it is diluted with, so the number of draws depends entirely on the amount per draw, and that amount has never been established for a person. The FDA record does show which presentations were being compounded: a 10 mg BPC 157 injection was recalled in December 2018 for lack of sterility assurance, and in July 2025 a 15 mg/10 mL vial was recalled, as was a combined BPC-157 and thymosin beta-4 injection at 10 mg/10 mg and 15 mg/15 mg. Vial size is a packaging fact, and it says what was in the glass rather than how long it should last anyone.

Question 10

How were these amounts administered in the studies?

Accepted Answer

In the 2003 rat Achilles experiment the compound was dissolved in saline with no carrier added and injected into the abdominal cavity once daily. The first injection came 30 minutes after the tendon was cut. The last came 24 hours before the animal was examined. Across the wider rat literature, a 2021 review reports the same dose range and the same equipotent routes regardless of the injury tested, which covers injection into the abdominal cavity, administration by mouth, and local application. Equipotent means the routes produced comparable effects in those animals. In people the record is three data points: a 2025 narrative review counts three pilot studies, covering intra-articular knee injection, interstitial cystitis, and intravenous safety. Intra-articular means into the joint space itself. A 2025 review in Arthroscopy calls the underlying work very early in vivo research on pharmacokinetics. None of this is a schedule for a person. It is the set of conditions under which an outcome was measured.

Question 11

How do mg, mcg and mL relate on a syringe?

Accepted Answer

One milligram is a thousand micrograms, so a 5 mg vial holds 5,000 mcg and a 10 mg vial holds 10,000 mcg. Milligrams and micrograms measure the compound itself, while millilitres measure the liquid it is dissolved in, and the two only connect once a diluent volume has been chosen. Concentration is the bridge between them: the total micrograms divided by the millilitres of diluent gives the micrograms per millilitre. A U-100 insulin syringe is marked in units rather than millilitres, and because one hundred units make a millilitre, a single unit mark is one hundredth of a millilitre. Multiplying the concentration in micrograms per millilitre by that hundredth gives the micrograms sitting behind each mark. The animal work expressed amounts per kilogram of body weight, a unit that appears on no syringe and does not transfer between species: the 2003 rat study reported micrograms, nanograms and picograms per kilogram, in animals weighing a few hundred grams. Our converter and reconstitution tools run these sums on figures you enter.

Question 12

Why do published protocols vary?

Accepted Answer

They vary less than it looks, and for a reason worth understanding. The 2003 Achilles study ran three levels spanning a millionfold range in one design, because the point was to map a dose-response curve rather than to find a working number. A 2021 review describes the same dose range being reused across completely different injuries, which is the opposite of variation. Human figures vary for a different reason: there is nothing to vary around. A 2026 review states that indications, dosing, frequency and duration all remain unknown, and the Phase 2 trial titled BPC 157 for Acute Hamstring Muscle Strain Repair is still recruiting. A 2025 systematic review adds a supply-side caveat. Adverse effects remain possible because of unregulated manufacturing, contamination, or unknown clinical safety, which means two vials labelled identically are not necessarily the same input. Where published amounts differ, then, it is because they answer different experimental questions.

BPC-157 protocols in the published literature